Paradoxical absence of a prothrombotic phenotype in a mouse model of severe hyperhomocysteinemia

Blood

Volumn 119, Issue 13, 2012, Pages 3176-3183

  Dayal, Sanjana ^a   Chauhan, Anil K ^a   Jensen, Melissa ^a   Leo, Lorie ^a   Lynch, Cynthia M ^a   Faraci, Frank M ^a   Kruger, Warren D ^b   Lentz, Steven R ^a  

^a UNIVERSITY OF IOWA   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTATHIONINE BETA SYNTHASE; HOMOCYSTEINE; METHIONINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOLE; ARTERY THROMBOSIS; ARTICLE; BLOOD VESSEL DIAMETER; BRAIN BLOOD VESSEL; CAROTID ARTERY INJURY; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; FEMALE; GENE MUTATION; HEMODYNAMICS; HEMOSTASIS; HOMOCYSTINURIA; HYPERHOMOCYSTEINEMIA; INFERIOR CAVA VEIN; MALE; MESENTERIC ARTERY; MOUSE; NONHUMAN; PHENOTYPE; PHOTOCHEMISTRY; PRIORITY JOURNAL; THROMBOSIS; TRANSGENE; VASCULAR ENDOTHELIUM; VASODILATATION; VEIN LIGATION; VEIN THROMBOSIS;

EID: 84859188970     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-09-380568     Document Type: Article

References (41)

1. Mudd SH, Finkelstein JD, Refsum H, et al. Homocysteine and its disulfide derivatives: a suggested consensus terminology. Arterioscler Thromb Vasc Biol. 2000;20(7):1704-1706. (Pubitemid 30470583)
2. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. J Am Med Assoc. 2002;288(16):2015- 2022.
3. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J Am Med Assoc. 1995;274(13):1049-1057.
4. den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost. 2005;3(2):292-299. (Pubitemid 41623617)
5. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. 1985;37(1):1-31. (Pubitemid 15138674)
6. Yap S, Boers GH, Wilcken B, et al. Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: a multicenter observational study. Arterioscler Thromb Vasc Biol. 2001;21(12):2080-2085. (Pubitemid 34219765)
7. Armitage JM, Bowman L, Clarke RJ, et al. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. J Am Med Assoc. 2010;303(24):2486-2494.
8. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354(15):1578-1588.
9. Clarke R, Halsey J, Lewington S, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med. 2010;170(18):1622-1631.
10. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354(15):1567-1577.
11. Lee M, Hong KS, Chang SC, Saver JL. Efficacy of homocysteine-lowering therapy with folic acid in stroke prevention: a meta-analysis. Stroke. 2010;41(6):1205-1212.
12. den Heijer M, Willems HP, Blom HJ, et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial. Blood. 2007;109(1):139-144. (Pubitemid 46053054)
13. Eberhardt RT, Forgione MA, Cap A, et al. Endothelial dysfunction in a murine model of mild hyperhomocyst (e) inemia. J Clin Invest. 2000;106(4):483-491. (Pubitemid 30666381)
14. Cheng Z, Jiang X, Kruger WD, et al. Hyperhomocysteinemia impairs endothelium-derived hyperpolarizing factor-mediated vasorelaxation in transgenic cystathionine beta synthase-deficient mice. Blood. 2011;118(7):1998-2006.
15. Jiang X, Yang F, Tan H, et al. Hyperhomocystinemia impairs endothelial function and eNOS activity via PKC activation. Arterioscler Thromb Vasc Biol. 2005;25(12):2515-2521. (Pubitemid 43732272)
16. Dayal S, Arning E, Bottiglieri T, et al. Cerebral vascular dysfunction mediated by superoxide in hyperhomocysteinemic mice. Stroke. 2004;35(8):1957-1962. (Pubitemid 38971883)
17. Dayal S, Bottiglieri T, Arning E, et al. Endothelial dysfunction and elevation of S-adenosylhomocysteine in cystathionine beta-synthase-deficient mice. Circ Res. 2001;88(11):1203-1209. (Pubitemid 34132522)
18. Dayal S, Brown KL, Weydert CJ, et al. Deficiency of glutathione peroxidase-1 sensitizes hyperhomocysteinemic mice to endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2002;22(12):1996-2002. (Pubitemid 36025205)
19. Dayal S, Devlin AM, McCaw RB, et al. Cerebral vascular dysfunction in methionine synthase-deficient mice. Circulation. 2005;112(5):737-744. (Pubitemid 41099054)
20. Dayal S, Rodionov RN, Arning E, et al. Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia. Am J Physiol Heart Circ Physiol. 2008;295(2):H816-H825.
21. Devlin AM, Arning E, Bottiglieri T, Faraci FM, Rozen R, Lentz SR. Effect of Mthfr genotype on diet-induced hyperhomocysteinemia and vascular function in mice. Blood. 2004;103(7):2624-2629. (Pubitemid 38393016)
22. Lentz SR, Erger RA, Dayal S, et al. Folate dependence of hyperhomocysteinemia and vascular dysfunction in cystathionine beta-synthase-deficient mice. Am J Physiol Heart Circ Physiol. 2000;279(3):H970-H975.
23. Dayal S, Wilson KM, Leo L, Arning E, Bottiglieri T, Lentz SR. Enhanced susceptibility to arterial thrombosis in a murine model of hyperhomocysteinemia. Blood. 2006;108(7):2237-2243. (Pubitemid 44497505)
24. Jacovina AT, Deora AB, Ling Q, et al. Homocysteine inhibits neoangiogenesis in mice through blockade of annexin A2-dependent fibrinolysis. J Clin Invest. 2009;119(11):3384-3394.
25. Tan H, Jiang X, Yang F, et al. Hyperhomocysteinemia inhibits post-injury reendothelialization in mice. Cardiovasc Res. 2006;69(1):253-262. (Pubitemid 41818973)
26. Wang L, Chen X, Tang B, Hua X, Klein-Szanto A, Kruger WD. Expression of mutant human cystathionine beta-synthase rescues neonatal lethality but not homocystinuria in a mouse model. Hum Mol Genet. 2005;14(15):2201-2208. (Pubitemid 41418019)
27. Wang L, Jhee KH, Hua X, DiBello PM, Jacobsen DW, Kruger WD. Modulation of cystathionine beta-synthase level regulates total serum homocysteine in mice. Circ Res. 2004;94(10):1318-1324. (Pubitemid 38724477)
28. Gupta S, Kuhnisch J, Mustafa A, et al. Mouse models of cystathionine beta-synthase deficiency reveal significant threshold effects of hyperhomocysteinemia. FASEB J. 2009;23(3):883-893.
29. Sobey CG, Faraci FM. Effects of a novel inhibitor of guanylyl cyclase on dilator responses of mouse cerebral arterioles. Stroke. 1997;28(4):837-842.
30. Wilson KM, Lynch CM, Faraci FM, Lentz SR. Effect of mechanical ventilation on carotid artery thrombosis induced by photochemical injury in mice. J Thromb Haemost. 2003;1(12):2669-2674.
31. Fay WP, Parker AC, Ansari MN, Zheng X, Ginsburg D. Vitronectin inhibits the thrombotic response to arterial injury in mice. Blood. 1999;93(6):1825-1830. (Pubitemid 29128482)
32. Chauhan AK, Motto DG, Lamb CB, et al. Systemic antithrombotic effects of ADAMTS13. J Exp Med. 2006;203(3):767-776.
33. McDonald AP, Meier TR, Hawley AE, et al. Aging is associated with impaired thrombus resolution in a mouse model of stasis induced thrombosis. Thromb Res. 2010;125(1):72-78.
34. Dayal S, Lentz SR. Murine models of hyperhomocysteinemia and their vascular phenotypes. Arterioscler Thromb Vasc Biol. 2008;28(9):1596-1605.
35. Loscalzo J. Homocysteine trials-clear outcomes for complex reasons. N Engl J Med. 2006;354(15):1629-1632.
36. Maclean KN, Sikora J, Kozich V, et al. A novel transgenic mouse model of CBS-deficient homocystinuria does not incur hepatic steatosis or fibrosis and exhibits a hypercoagulative phenotype that is ameliorated by betaine treatment. Mol Genet Metab. 2010;101(2-3):153-162.
37. Maclean KN, Sikora J, Kozich V, et al. Cystathionine beta-synthase null homocystinuric mice fail to exhibit altered hemostasis or lowering of plasma homocysteine in response to betaine treatment. Mol Genet Metab. 2010;101(2-3):163-171.
38. Hofmann MA, Lalla E, Lu Y, et al. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest. 2001;107(6):675-683. (Pubitemid 32225353)
39. Troen AM, Lutgens E, Smith DE, Rosenberg IH, Selhub J. The atherogenic effect of excess methionine intake. Proc Natl Acad Sci U S A. 2003;100(25):15089-15094. (Pubitemid 37518021)
40. Wilson KM, McCaw RB, Leo L, et al. Prothrombotic effects of hyperhomocysteinemia and hypercholesterolemia in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2007;27(1):233-240. (Pubitemid 46360404)
41. Fichtlscherer S, Breuer S, Zeiher AM. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: further evidence for the existence of the "vulnerable" patient. Circulation. 2004;110(14):1926-1932. (Pubitemid 39331903)